腾瑞制药筹备上市：董事长叶桃控股37%，曾任职辉瑞制药

Core Viewpoint - Shanghai Tengrui Pharmaceutical Co., Ltd. is experiencing revenue growth in 2024 due to increased sales of its proprietary innovative drug "Aifujifu" and agency drugs, although the company has a limited number of commercialized proprietary products [2] Group 1: Company Overview - Tengrui Pharmaceutical was established in 2010, focusing on biopharmaceuticals, including chemical raw materials and oral solid preparations, and operates as a high-tech biopharmaceutical enterprise covering drug research and development, production, and marketing [6] - The company holds 33 national drug approval numbers, including one national class I biological product, and has obtained 11 global and national invention patent authorizations [6] - The chairman and general manager, Ye Tao, directly and indirectly controls 36.84% of the company's shares, with investments from Junlian Capital, CICC Capital, Guoxin Innovation Investment, Yaokin Capital, and IDG Capital [6] Group 2: Financial and Strategic Developments - Tengrui Pharmaceutical's revenue growth in 2024 is attributed to the increase in sales of "Aifujifu" and agency drugs, with plans to expand the sales scale of "Aifujifu" [2] - The innovative drug "Baqi Enzyme," currently under development, is expected to be launched in 2026 and is anticipated to become a new growth point for the company's performance [2] - During the counseling period, Ye Tao and Liu Yang, as actual controllers of Suzhou Shenzhiruitai Enterprise Management Partnership, plan to acquire 151 million shares (26.54% of total shares) of Honghui Fruits and Vegetables Co., Ltd. [4]